Edwards Lifesciences (EW) Short-term Investments (2011 - 2026)

Edwards Lifesciences has reported Short-term Investments for 16 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Short-term Investments rose 70.53% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 70.53% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 38.42% from the prior year.
• Short-term Investments was $1.3 billion for Q2 2026 at Edwards Lifesciences, up from $1.2 billion in the prior quarter.
• The five-year high for Short-term Investments was $1.3 billion in Q2 2026, with the low at $317.7 million in Q2 2022.
• Average Short-term Investments over 5 years is $700.3 million, with a median of $495.7 million recorded in 2022.
• The largest YoY upside for Short-term Investments was 197.31% in 2022 against a maximum downside of 26.11% in 2022.
• Over 5 years, Short-term Investments stood at $446.3 million in 2022, then advanced by 12.14% to $500.5 million in 2023, then soared by 85.95% to $930.7 million in 2024, then surged by 38.42% to $1.3 billion in 2025, then grew by 4.49% to $1.3 billion in 2026.
• The last three Short-term Investments figures came in at $1.3 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.